Robert Shellman, MD
Pulmonary Disease · Shelbyville, INNPI 1659339927
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 795 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations.
Across 795 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$872
- Boehringer Ingelheim$807
- Harmony Biosciences LLC$793
- Sanofi$780
- plus $7K from 42 others
What the payments were for
- Food & beverage$15,55496%
- Education$6044%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$633
- NUCALA$585
- TEZSPIRE$344
- BREZTRI$265
- TRELEGY ELLIPTA$224
- Prolastin-C$160
- FARXIGA$143
- BREZTRI AEROSPHERE$129
- XOLAIR$125
- AREXVY$125
How this compares
$16,158 in reported general payments places this provider in the 85th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 57 | $711,680 |
| WakixPitolisant Hcl | 45 | $652,295 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 641 | $547,854 |
| GlassiaAlpha-1-Proteinase Inhibitor | 32 | $431,785 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 18 | $310,420 |
| XywavSodium,calcium,mag,pot Oxybate | 13 | $263,837 |
| Dupixent SyringeDupilumab | 63 | $238,369 |
| Fasenra PenBenralizumab | 34 | $191,595 |
| UptraviSelexipag | 11 | $184,246 |
| AdempasRiociguat | 12 | $169,323 |
| Spiriva RespimatTiotropium Bromide | 237 | $158,893 |
| XolairOmalizumab | 34 | $155,352 |
| OpsumitMacitentan | 12 | $151,068 |
| TezspireTezepelumab-Ekko | 34 | $142,896 |
| Dupixent PenDupilumab | 36 | $141,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $807 | $997,940507 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $2,381 | $986,4071,398 claims |
| Harmony Biosciences LLCWakix | $793 | $652,29545 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $731 | $431,78532 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $146 | $335,31423 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $3,638 | $248,380211 claims |
| BayerAdempas | $20 | $169,32312 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $119 | $59,084181 claims |
| PfizerEliquis | $41 | $19,34617 claims |
| Axsome Therapeutics, Inc.Sunosi | $339 | $12,95913 claims |
| Covis Pharma GmbHAlvesco | $48 | $7,07219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Shelbyville
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.